Sign In
Buy HOTH
$1.36
+0 (+0%)
At Close: Jun 03, 2026
Why Hoth Therapeutics (HOTH) Stock Is Surging After Hours Today
02:45am, Thursday, 28'th May 2026
Hoth Therapeutics stock surged after announcing its Rocket One rebrand and new AI chip technology focus.
Company Adopts Space-Focused Identity, New Ticker "RKTO," and Exclusive License of AI Chip Architecture Designed for Ultra-Low-Power, Radiation-Tolerant Computing in Space and Defense Applications HOB
Hoth Therapeutics Awarded U.S. Patent for Cancer-Fighting HT-KIT Oncology Platform
08:18am, Tuesday, 26'th May 2026
Allowed Claims Cover Composition-of-Matter and Methods Targeting MS4A6A Pre-mRNA Splicing to Reduce Surface Expression of the High-Affinity IgE Receptor (FcεRI); Strengthens Intellectual Property Fou
AI Chip Energy Efficiency: Hoth Therapeutics Restructures as Rocket One Inc. to Enter the AI Semiconductor Infrastructure Market with Acquisition of Exclusive Rights to Next Generation AI Semiconductor Acceleration Technology Built on Non-Volatile Nanomagnetic Semiconductor Architecture
08:17am, Tuesday, 19'th May 2026
Company Targets Power Demands of AI Data Centers Through Patented Nanomagnetic Semiconductor and Spintronic Computing Technologies for AI, Defense, and Space Applications HOBOKEN, N.J., May 19, 2026 /
Regulatory Clearance in Spain Advances Randomized, Placebo-Controlled Study; Patients Show Meaningful Reductions in EGFR-Inhibitor Skin Toxicities with No Treatment Disruptions NEW YORK, May 5, 2026
Statistically Significant Reduction in Srebf1 (Fat Production) and Increased Pparα (Fat Metabolism) Position GDNF as Next-Generation Therapy for MAFLD and Obesity NEW YORK, April 14, 2026 /PRNewswire
Statistically Significant Reduction in Srebf1 (Fat Production) and Increased Pparα (Fat Metabolism) Position GDNF as Next-Generation Therapy for MAFLD and Obesity NEW YORK, April 13, 2026 /PRNewswire
Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering
04:05pm, Thursday, 02'nd Apr 2026
NEW YORK, April 2, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet medical needs, today ann
Hoth Therapeutics Announces $2.0 Million Registered Direct Offering
01:52pm, Wednesday, 01'st Apr 2026
NEW YORK, April 1, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet medical needs, today ann
Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA ≤1 by Week Six
08:14am, Wednesday, 01'st Apr 2026
Over 65% of Patients Reported Reduced Pain and Itching; Zero Disruptions to EGFR Cancer Therapy with ~99% Lower Systemic Exposure NEW YORK, April 1, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDA
Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology
08:07am, Tuesday, 31'st Mar 2026
Technology Selectively Shuts Down Cancer Reproducing Cells Patent Covers Splice-Switching Oligonucleotide Platform Designed to Induce Apoptosis of Mast Cells NEW YORK, March 31, 2026 /PRNewswire/ -- H
Hoth Therapeutics Deploys OpenClaw™ AI Platform to Accelerate Drug Discovery
08:30am, Thursday, 26'th Mar 2026
NEW YORK, March 26, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced the deployment of OpenClaw™, an advanced AI-enabled comp
PK studies of topical HT-001 reveal limited systemic absorption and ~99% reduced systemic levels as compared to FDA approved oral formulations . Safety and tolerability findings included: No serious a
HT-VA restores cholesterol to control-diet levels and maintains lower triglycerides compared with semaglutide in western diet–fed female mice Treatment preserved hepatic autophagy and maintained nor
Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program
08:31am, Wednesday, 04'th Mar 2026
AI Integration Supports IND Preparation & Phase 1 Progression for Rare KIT-Driven Cancers NEW YORK, March 4, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmace
